Trials / Completed
CompletedNCT05468307
A Study of GC203 TIL in Advanced Gynecologic Tumors (10hospital)
A Clinical Study of Engineered Tumor Infiltrating Lymphocytes Injection (GC203 TIL) in Patients With Advanced Gynecologic Tumors
- Status
- Completed
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- Shanghai Juncell Therapeutics · Industry
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is to investigate the safety and efficacy on TIL engineered with membrane-binding cytokine (GC203 TIL) for the treatment of patients with advanced gynecologic tumors. Autologous TILs from tumor resections or biopsies are first gene modified (engineered with membrane-binding cytokine) and than expanded before i.v. infusion into the patient after NMA lymphodepletion treatment with cyclophosphamide.
Conditions
- Advanced Gynecologic Tumors
- TIL Engineered With Membrane-Binding Cytokine
- Treatment Side Effects
- Effects of Immunotherapy
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Membrane Bound Cytokine Modified TIL | Adoptive transfer of 2x10\^8-1x10\^10 autologous TIL engineered with membrane-binding cytokine to patients i.v. in 30-120 minutes. |
Timeline
- Start date
- 2022-03-10
- Primary completion
- 2024-12-30
- Completion
- 2024-12-30
- First posted
- 2022-07-21
- Last updated
- 2025-12-11
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05468307. Inclusion in this directory is not an endorsement.